Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Respiratory Syncytial Virus Infections 1Lymphoma, Follicular 1COVID-19 1Autoimmune Diseases 1

Interventions

telitacicept 3fludarabine 3Prednisone 3Cyclophosphamide 3Specimen Handling 2Nivolumab 2Antilymphocyte Serum 2thymoglobulin 1remdesivir 1prednylidene 1deltacortene 1carmustine, poliferprosan 20 drug combination 1cabozantinib 1Vitamin D 1Valsartan 1Pyridostigmine Bromide 1Population Groups 1Platinum Compounds 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Music Therapy 1Melphalan 1Ipilimumab 1Infliximab 1Immunoglobulins, Intravenous 1Hydroxychloroquine 1Fish Oils 1Fatty Acids, Omega-3 1Etoposide 1Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Autoimmune Diseases × remdesivir × Clear all
NCT06817889 2026-06-03

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Fred Hutchinson Cancer Center

Phase 2 Recruiting
60 enrolled

Autoimmune Diseases, Respiratory Syncytial Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡